Anthropic's Claude Expands Into Drug Discovery Work
Biotech developers report using Claude to speed molecular design, antibody engineering and manufacturing documentation review.
Updated on Nov. 2, 2026 in Biotech
Live Poll
Do you think AI-assisted drug development will lower what you pay for medicine?
Anthropic has expanded Claude's role in pharmaceutical research through work with several biotechnology companies. The collaborations span cell therapy redesign, antibody candidate development and manufacturing document review.
Why it matters
The reported results suggest AI tools could shorten laborious stages of early drug development and regulatory preparation. The examples come from company-reported work, so their broader significance remains to be tested.
Claude generated approximately 35,000 molecular designs in one month, and three designs were capable of binding to IgE. Enveda's documentation review identified all 11 problems previously found by human reviewers plus seven additional issues, though no independent validation of these outcomes has been reported.
The players
Anthropic
Anthropic is the artificial intelligence company that develops the Claude family of AI models.
Generate Biomedicines
Generate Biomedicines is a biotechnology company focused on AI-driven protein therapeutics and cell therapy development.
Bristol Myers Squibb
Bristol Myers Squibb is a multinational pharmaceutical company that is assessing clinical study plans with Claude.
The details
Generate Biomedicines used Claude Code to modify a CAR T-cell therapy component, creating space for genetic instructions aimed at solid tumours. Divergence Labs used Claude to develop antibody candidates for a potential food-allergy treatment, while BigHat Biosciences paired it with automated laboratory equipment to improve two antibody fragments, testing roughly 1,010 variations over ten weeks.
Timeline
One month: Divergence Labs' system generated approximately 35,000 molecular designs.
Ten weeks: BigHat researchers tested approximately 1,010 antibody fragment variations.
The Tech Race
The expansion places Claude alongside other frontier AI systems competing for scientific and enterprise use cases in life sciences. It shows AI developers pushing from general-purpose assistance into specialised laboratory and regulatory workflows.
If the reported gains hold up, patients could eventually see faster development of cell and antibody therapies. Near term, the changes are mainly relevant to researchers and drug developers rather than to everyday consumers.
The takeaway
AI tools are moving from writing code into the slower, regulated parts of drug development. Readers should watch whether these early laboratory gains translate into clinical results.
Further reading
For more on AI applied to laboratory science, explore Biotech coverage.
Live Poll
Do you think AI-assisted drug development will lower what you pay for medicine?
